



Press release

Valbiotis announces an exclusive distribution agreement in the Middle East

After Asia, a new milestone in international expansion

- An exclusive partnership with Mena Nutrition, a specialist in the health and nutrition products sector.
- Mena Nutrition will promote and market Valbiotis products in Saudi Arabia, Lebanon, and Iraq.
- The company anticipates generating initial revenues starting late 2026.

La Rochelle, January 8, 2026 (5:40 p.m. CEST) – **Valbiotis** (FR0013254851 ALVAL, eligible for PEA/SME classification), is a French laboratory specialized in the design and distribution of scientifically tested dietary supplements to support health at every stage of life. Valbiotis has signed an exclusive distribution agreement with Mena Nutrition, a company that specializes in the marketing, commercialization, and distribution of health and nutrition products in the Middle East and North Africa.

The strength of an established local player in the health and nutrition sector

Under this agreement, Mena Nutrition will promote and distribute Valbiotis products in Saudi Arabia, Lebanon, and Iraq. Based in the United Arab Emirates, Mena Nutrition has a strong presence, with more than 20 years of experience in these markets (<https://www.menanutrition.com/>).

Mena Nutrition has a proven track record in deploying local medical promotion strategies. The company has successfully recruited and managed teams of medical representatives, showcasing its capabilities in this area. It has extensive experience in optimizing commercial policies in pharmacies and managing logistics and supply chains through established distribution partners in each target country, including Zimmo Trading in Saudi Arabia and Holdal Group in Lebanon.

Mena Nutrition's regulatory experts possess extensive knowledge of the regulatory requirements of Middle Eastern markets and maintain close relationships with various local health authorities regarding administrative procedures, registration, and imports.

An assertive strategy to position Valbiotis^{PRO} products as the gold standard in the prevention of cardiometabolic conditions

The strategy for promoting Valbiotis products will be primarily medical, with the aim of making Valbiotis^{PRO} products the gold standard in the prevention of cardiometabolic conditions in the region. This will be achieved by leveraging the high level of scientific evidence supporting the products. Commercialization will not require any direct investment from Valbiotis. Valbiotis products will be sold in pharmacies, with Mena Nutrition relying on the logistical capabilities and sales forces of its distribution partners in each target country.

Commercialization is expected to begin in late 2026, after registration with the health authorities in each country has been completed.

Middle Eastern countries represent high-potential markets for Valbiotis^{PRO} products, given the prevalence of diseases associated with metabolic imbalances, such as hypercholesterolemia, and pre-diabetes. Type 2 diabetes, overweight/obesity, high blood pressure, and fatty liver disease associated with metabolic dysfunction (MASLD) are all significantly higher than global averages in this region.

"This agreement represents a new phase in the acceleration of our international strategy, following the announcement in November of our entry into Asian markets. Month after month we are building solid foundations for our commercial deployment in high-potential countries, while ramping-up our activities in the French market. These advances reinforce our confidence for 2026, when we expect to begin reaping the first benefits of our transformation. Our sights are set on deploying an original, revenue-generating model in the international dietary supplement industry. I would like to express my gratitude to all the teams at Mena Nutrition for their commitment to working with us. Together, we are embarking on a new venture, and I am confident that it will fulfil all its promises", according to **Sébastien Peltier, President and co-founder** of Valbiotis.

A strategic partnership at the heart of Valbiotis brand's international expansion

This new partnership is fully aligned with Valbiotis' strategy, initiated from France, to deploy and expand its brand internationally. It represents a pivotal step in the company's ambition to extend Valbiotis solutions and expertise beyond France's borders, while consolidating its scientific and innovative positioning. This partnership reinforces the brand's commitment to a responsible and rigorous approach to preventive health, both in France and internationally.

About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis

Caroline LAMBERTI

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial Communication / Seitosei.Actifin

Marianne PY

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com



Name: Valbiotis

ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.